Market Trends Fulcrum Therapeutics, MyoKardia end agreement on cardiomyopathy treatmentsBy admin8996erT0allMarch 5, 2025 MyoKardia, now part of Bristol Myers Squibb (NYSE:BMY), has ended an agreement signed in July 2020 to work with Fulcrum…
